Laws · Ongoing coverage · 1,656 words

DEA Medical Marijuana Registrations: Who Qualifies and What Changes

This hub explains how DEA registration works for medical marijuana and what the first registrations issued in October 2026, as reported by MJBizDaily, could mean. It covers the Controlled Substances Act registration framework, the long-standing University of Mississippi monopoly on federally authorized cultivation for research, and the rescheduling process that connects to Schedule III. It also separates DEA registration from state licensing and FDA drug approval, which are distinct legal gates. We update the page as the DEA, DOJ, and HHS publish rules, notices, and registrant information.

Last updated October 31, 2026 · 0 updates since publication
Close-up of a marijuana nugget delicately held by tweezers on a white background.
A DEA medical marijuana registration is federal authorization under the Controlled Substances Act to handle marijuana, such as growing, manufacturing, distributing, or dispensing it. It is separate from state licenses and FDA approval. MJBizDaily reported the first such registrations were issued on October 30, 2026.

Executive summary

The DEA has begun issuing medical marijuana registrations, a step that moves federal cannabis policy from rulemaking into licensing. MJBizDaily reported on October 30, 2026, that the first registrations had been issued. This page covers what a DEA registration is, why it matters, and how it differs from state licensure.

A DEA registration is the federal permission slip required by 21 U.S.C. § 822 for anyone who manufactures, distributes, dispenses, prescribes, or researches a controlled substance. For 56 years, marijuana sat in Schedule I under 21 U.S.C. § 812, where registrations were available almost exclusively for research. Moving marijuana out of Schedule I opens a lawful federal channel for medical supply. That channel runs through the same registration architecture used for opioids, stimulants, and testosterone.

The details of the first registrations are still emerging. CannIntel will add the recipients, registration categories, and counts to this page once they are confirmed in primary DEA or Federal Register documents. Until then, treat anything beyond the MJBizDaily headline as unverified.

Three things already hold for operators and investors:

  • A federal registration is not a state license, and a state license is not a federal registration.
  • Registration does not by itself resolve the conflict between the Controlled Substances Act and the Federal Food, Drug, and Cosmetic Act (FDCA), which governs unapproved drugs.
  • Tax relief under 26 U.S.C. § 280E depends on schedule placement, not on holding a registration.

Why this matters

Federal registrations affect an estimated multibillion-dollar medical market, millions of state-registered patients, and the tax and banking posture of every multistate operator (MSO).

State medical marijuana programs operate in roughly 40 states and the District of Columbia. They serve millions of registered patients, and the legal U.S. cannabis market is worth tens of billions of dollars a year across medical and adult-use channels. Until now, none of that activity had a federal registration framework. State-licensed businesses relied on enforcement discretion and the appropriations rider first adopted in 2014, known as Rohrabacher-Farr or Blumenauer.

The stakeholders break down as follows:

  • Patients gain a potential path to federally recognized medical access, including possible pharmacy dispensing, VA involvement, and insurance coverage. All of these depend on further rules.
  • Operators face a new compliance layer: Form 224 and Form 225 style registrations, recordkeeping under 21 CFR Part 1304, security under 21 CFR Part 1301, and quota and reporting obligations.
  • Researchers have long complained that Schedule I registration and the single federal supply source slowed clinical work. Registrations under the Medical Marijuana and Cannabidiol Research Expansion Act (Pub. L. 117-215, December 2022) were designed to ease that.
  • Investors must price in who gets federal registrations first, because early registrants may hold a durable edge in a licensed federal channel.
  • State regulators must decide how their programs interact with a federal system that could impose product, labeling, and chain-of-custody standards.

Our read: the registration is the first operational signal that federal reform is more than a scheduling label. The scheduling debate lasted years. Registration is where the economics are decided, because registrants control who can lawfully touch the plant under federal law.

Background and history

Marijuana moved from unregulated plant to Schedule I in 1970, and every attempt to move it since has stalled until the 2022-2026 sequence that led to these registrations.

1937-1970: Prohibition by tax, then by schedule

The Marihuana Tax Act of 1937 effectively criminalized the plant through a transfer-tax and registration scheme. The Supreme Court struck the Act down in Leary v. United States (1969) on Fifth Amendment grounds. Congress replaced it with the Controlled Substances Act (CSA) in 1970, which placed marijuana in Schedule I provisionally, pending a commission study. That commission, led by Raymond Shafer, recommended in 1972 that possession for personal use be decriminalized. President Nixon rejected the recommendation, and the Schedule I placement stayed.

1972-1994: The first rescheduling petitions

NORML petitioned in 1972 to reschedule marijuana. The petition ran through DEA proceedings for more than two decades. In 1988, DEA Chief Administrative Law Judge Francis Young recommended rescheduling after a lengthy hearing, finding marijuana one of the safest therapeutically active substances known. The DEA Administrator rejected that finding. In Alliance for Cannabis Therapeutics v. DEA (D.C. Cir. 1994), the court upheld the DEA's refusal, applying a five-part test for "currently accepted medical use."

1978-1992: The Compassionate IND program

Glaucoma patient Robert Randall won access to federal cannabis in 1976 after a court case. The resulting Compassionate IND program supplied government-grown cannabis to a small number of patients. It closed to new applicants in 1992. A handful of patients continued receiving federally grown cannabis for decades, which made the government's position that marijuana has no accepted medical use harder to sustain.

1996-2014: States move first

California passed Proposition 215 in 1996, becoming the first state to legalize medical marijuana. Dozens of states followed. In United States v. Oakland Cannabis Buyers' Cooperative (2001), the Supreme Court rejected a medical necessity defense to the CSA's manufacturing and distribution prohibitions. In Gonzales v. Raich (2005), it held that Congress could reach homegrown medical cannabis under the Commerce Clause.

Congress adopted the appropriations rider in December 2014, barring DOJ from spending funds to interfere with state medical programs. In United States v. McIntosh (9th Cir. 2016), the court read the rider as limiting prosecutions of people who comply with state law.

2016-2019: Supply bottleneck and the CBD carve-out

The University of Mississippi has held the federal research cultivation contract through NIDA since 1968. In 2016, DEA announced a policy to register additional growers. In August 2019, it disclosed that it had received applications from dozens of would-be growers, but few were approved over the following years. The result was years of litigation, including petitions by the Scottsdale Research Institute.

The FDA approved Epidiolex, a plant-derived CBD medicine, on June 25, 2018. The 2018 Farm Bill, signed December 20, 2018, removed hemp with no more than 0.3% delta-9 THC from the CSA. Together these created a split regime: hemp and FDA-approved CBD drugs outside Schedule I, and marijuana inside it.

2022-2024: Biden review, HHS recommendation, and the NPRM

On October 6, 2022, President Biden directed HHS and the Attorney General to review marijuana's scheduling and pardoned federal simple-possession offenses. President Biden signed the Medical Marijuana and Cannabidiol Research Expansion Act in December 2022 (Pub. L. 117-215). HHS recommended Schedule III on August 29, 2023, in a letter from Assistant Secretary Rachel Levine to DEA Administrator Anne Milgram. That letter became public in January 2024 after a records request.

DOJ published a notice of proposed rulemaking (NPRM) on May 21, 2024, proposing to move marijuana to Schedule III. A formal hearing before an ALJ was scheduled for January 2025. It was stayed amid a dispute over participant selection and DEA procedure, and the process stalled as the administration changed.

2025-2026: Executive action and implementation

President Trump signed an executive order on December 18, 2025, directing the Attorney General to expedite completion of the rescheduling process and highlighting medical research and CBD access. The registrations reported by MJBizDaily on October 30, 2026, are the first visible implementation step on the registration side. For the legal mechanics, see the framework section below.

A parallel event shapes the same market. Congress's November 2025 appropriations law redefined hemp in a way that restricts many intoxicating hemp-derived products, including those built on THCA flower. The change takes effect one year after enactment, around November 12, 2026.

Key players

Federal power over registrations is split among DOJ, DEA, HHS, and FDA, while advocacy and industry groups push in opposite directions.

Drug Enforcement Administration (DEA)

The DEA, through its Diversion Control Division, issues registrations under 21 U.S.C. § 823 and 21 CFR Part 1301. It also sets production quotas for Schedule I and II substances under 21 U.S.C. § 826. Its Administrator, Terrance Cole, was confirmed in 2025.

Department of Justice

The Attorney General holds delegated scheduling authority under 21 U.S.C. § 811 and sets the rulemaking path. The Office of Legal Counsel's views on treaty obligations under the Single Convention on Narcotic Drugs (1961) have shaped how DOJ frames any registration regime.

HHS, FDA, and NIDA

HHS supplies the binding scientific and medical evaluation under § 811(b). The FDA controls drug approval under the FDCA. NIDA oversees the federal research supply. Registrations do not displace FDA's authority over unapproved drugs, so product pathways remain contested.

Industry: MSOs and licensed operators

Large multistate operators such as Curaleaf, Trulieve, Green Thumb Industries, Verano, and Cresco Labs have lobbied for Schedule III primarily for 280E relief. They are also the likeliest applicants for federal registrations given their compliance infrastructure. The US Cannabis Council and the National Cannabis Industry Association represent the broader industry in Washington.

Advocates for reform

NORML, Americans for Safe Access, and the Marijuana Policy Project support rescheduling but have said that Schedule III alone is insufficient. They favor descheduling and say that a federal registration scheme could burden small and social-equity operators.

Opposition

Smart Approaches to Marijuana, led by Kevin Sabet, opposes rescheduling and has argued that it would send the wrong public-health message and benefit large operators. Some law-enforcement groups have raised similar objections.

Legal and regulatory framework

Registration authority comes from the Controlled Substances Act, but marijuana's schedule placement, FDA status, and international treaty duties determine what a registration actually permits.

The Controlled Substances Act

  • 21 U.S.C. § 802 defines marijuana and controlled substance terms.
  • 21 U.S.C. § 811 governs scheduling by rulemaking, including the HHS role.
  • 21 U.S.C. § 812 contains the schedules. Schedule I requires high abuse potential, no currently accepted medical use, and a lack of accepted safety under medical supervision. Schedule III requires moderate to low dependence potential and accepted medical use.
  • 21 U.S.C. § 822 requires registration for manufacture, distribution, and dispensing, and § 823 sets the criteria, including public-interest factors for bulk manufacturers.
  • 21 U.S.C. § 841 criminalizes unregistered manufacture and distribution.

Regulations

Frequently asked questions

What is a DEA medical marijuana registration?

It is a federal registration issued by the Drug Enforcement Administration under the Controlled Substances Act. It authorizes a business or practitioner to handle a controlled substance, in this case marijuana, for specified activities such as cultivation, manufacturing, distribution, or dispensing. Registration is activity-specific and location-specific, and holders must follow DEA recordkeeping, security, and reporting requirements.

Has the DEA issued its first medical marijuana registrations?

MJBizDaily reported on October 30, 2026, that the first DEA medical marijuana registrations were issued. Check the DEA Diversion Control Division and Federal Register notices for official details on registrants, registration types, and scope. This page will be updated as primary-source documents confirm specifics.

How is a DEA registration different from a state cannabis license?

A state license authorizes cannabis activity under state law, and the state regulator issues it. A DEA registration authorizes handling of a controlled substance under federal law. Holding one does not automatically give the other. Businesses in state programs have historically operated without DEA registration, which is why federal and state frameworks still conflict.

Who has historically been federally authorized to grow marijuana?

For decades, the University of Mississippi, under a National Institute on Drug Abuse contract, was the only federally authorized cultivator of marijuana for research. The DEA said in 2019 that it planned to register additional growers. It later registered some research-focused manufacturers, but progress was slow and contested.

How does rescheduling to Schedule III relate to DEA registrations?

Marijuana is currently Schedule I. In 2024 the Department of Justice proposed moving it to Schedule III, which recognizes accepted medical use and lower abuse potential than Schedule I. Registration requirements still apply to Schedule III substances, so rescheduling changes the regulatory category and research rules but does not remove DEA oversight.

Does a DEA registration make marijuana legal federally?

No. Registration permits only the specific activities the DEA authorizes for that registrant. Marijuana remains a controlled substance, and activity outside the registration, including most state-licensed commercial sales, is not covered. Unregistered handling remains subject to the Controlled Substances Act unless Congress or the agency changes the law.

Does DEA registration mean doctors can prescribe marijuana?

Not by itself. Physicians generally hold DEA registrations to prescribe controlled substances, but prescribing requires an FDA-approved drug. Today's state medical programs use physician recommendations or certifications, not federal prescriptions. FDA approval of a marijuana-derived product, or a separate legal pathway, would be needed to change that.

What do applicants need to do to get registered?

Applicants submit a DEA application for the relevant activity, such as manufacturing, and the DEA reviews qualifications, security, and compliance plans. Marijuana growers must also meet additional treaty-related requirements, including the DEA's role in controlling the supply. Registrants face inspections, inventory and recordkeeping rules, and ongoing reporting.

Who is affected by the first registrations?

The most direct effects fall on registered cultivators and manufacturers, federal researchers, and the companies that supply them. State-licensed operators, patients, and dispensaries are not automatically affected. Their position depends on how the DEA defines registrant eligibility and on any related rescheduling or legislative action.

Where can I find official DEA registration information?

The primary sources are the DEA Diversion Control Division website, Federal Register notices from the DEA and Department of Justice, and FDA and HHS statements on marijuana's medical use. Trade press such as MJBizDaily reports developments, but regulatory text and registrant lists should be verified in official documents.

DEAmedical marijuanareschedulingfederal cannabis policyControlled Substances Actmarijuana research
The CannIntel Daily

The cannabis newsletter you forward to your team.

Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.

No spam. Unsubscribe with one click. 21+ only.